Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).

Trial Details

NCT ID
NCT07565220
Phase
PHASE1
Sponsor
Sawa Ito, MD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Thiotepa
  • Fludarabine
  • Busulfan
  • PBSC infusion
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Patients must be considered appropriate candidates for either the low- or high-intensity conditioning regimen for allogeneic hematopoietic stem cel…
  • Age 50-70 years old or
  • Age 18-49 and unfit for a conventional myeloablative conditioning regimen per the treating physician
  • Patients have one of the following diagnoses:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →